Selegiline
Emsam (selegiline) is a small molecule pharmaceutical. Selegiline was first approved as Emsam on 2006-02-27. It is used to treat alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, and schizophrenia in the USA. The pharmaceutical is active against amine oxidase [flavin-containing] B. In addition, it is known to target amine oxidase [flavin-containing] A.
| Trade Name | Emsam |
|---|---|
| Common Name | Selegiline |
| Indication | alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, schizophrenia |
| Drug Class | Mao inhibitors, type B |
